Note: Descriptions are shown in the official language in which they were submitted.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-1-
IRRADIATION DEVICE
This invention relates to an irradiation device for insertion into an orifice
of the body for
providing photodynamic therapy or diagnosis of diseases, lesions and
conditions thereof.
An example of an orifice of the body where photodynamic treatment is of
benefit is the
female reproductive tract. Conditions affecting the female reproductive tract
are discussed below.
Similar conditions, or conditions that respond to similar treatments, can
arise in other orifices,
such as the rectum, ear or nose.
The human papillomavirus (HPV) is a virus that can infect the skin and mucus
membranes
in humans. More than 100 different types of HPV have been identified. Several
HPV types are
transmitted through sexual activity and are pathogenic. HPV is estimated to be
the most common
sexually transmitted infection in the US. Several hundred million women
worldwide are infected
with HPV once in their life-time (-70%), with the highest prevalence, 20-30%,
occurring in
young women. These viruses can cause infections in the female genitalia and
result in female
genitalia diseases like genital warts, dysplasia and cervical cancer.
Cervical cancer is a life-threatening disease and is today the third most
common cancer
form among women world wide. Scientists agree that there is a strong
correlation between the
development of cervical cancer and HPV. Persistent HPV infection of the cervix
may induce cell
abnormalities including cervical intraepithelial neoplasia (CIN), precancerous
lesions, and
ultimately cervical cancer.
Fortunately mild cellular abnormalities including CIN1 have a high degree of
spontaneous
regression (> 60%), and this is a condition that is normally only followed up
by colposcopy.
Moderate to severe CIN (C1N2 and C1N3) have a lower degree of spontaneous
regression and a
higher risk of progression. Patients with CIN2 and CIN3 are therefore
conisized, usually by
surgical procedures including diathermia, laser conisation and hysterectomy.
The efficacy is
about 90%, but side effects are disturbing, causing increased risk of
bleeding, infection, stenosis,
infertility and preterm labour.
If not treated, the precancerous cells will progress into more severe forms
like carcinoma
and neuroendocrine carcinoma. Treatment methods for cervical cancer are, as
with most other
cancer forms, dependent on the development stage of the disease. Treatment of
early stage
cervical cancer is normally various forms of surgery, while late stage
cervical cancer is treated
with surgery in combination with radiation therapy and chemotherapy. The most
common
chemotherapy of cervical cancer includes use of cisplatin. It is estimated
that around 1.1,000
women a year will be diagnosed with cervical cancer, and that almost 4,000
will die from the
disease. The degree of survival (over 5 years) depends on the stage of the
disease and is, on
average, above 50%.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-2-
Photodynamic therapy (PDT) is a therapeutic modality using a combination of
light and a
photosensitizer. When illuminated at a suitable wavelength the photosensitizer
or "PDT drug"
reacts with tissue oxygen to form oxygen radicals that interact with cellular
organelles including
the mitochondria and cell membranes. These interactions cause cell necrosis or
apoptosis
(programmed cell death). PDT is today used clinically for the treatment of
several diseases,
including various skin diseases.
Typical products for use in skin PDT are Metvix (Galderma, Switzerland) and
Levulan
(Dusa Pharmaceuticals Inc,Wilmington, USA).
A range of photosensitizers are known from the scientific literature. One type
of such
compounds is per se toxic to target cells or species or have light emitting
properties when exposed
to light. Such compounds have a relatively large molecular weight and are
often complex
molecules like phthalocyanines, chlorines, porphyrins and psoralens. Another,
more clinically
useful, type of compound are photosensitizer precursors that per se are not
phototoxic or light
emitting, but form photo-active compounds, e.g. endogenous porphyrins, in
vivo. Such
compounds are typically 5-aminolevulinic acid (5-ALA) and derivatives of 5-ALA
like 5-ALA
esters, and will be referred to hereafter as "precursors".
There is currently no product on the market for PDT or diagnosis of diseases,
lesions or
conditions of the cervix. However, there are several scientific reports on
clinical research related
to PDT of the cervix including PDT of human papillomavirus infections.
In a recently published study (P. Soergel et al, Lasers in Surgery and
Medicine 40:611-615
(2008)), 24 patients with a CIN2 or CIN3 or a persistent C1N1 received local
application of 5-
ALA hexylester in a thermogel formulation. The patients were advised to stay
supine for the next
3-5 hours before illumination which was performed for 17 minutes with a laser
at a high light
dose of 100 J/cm2. At 2-3 months later, the clinical effect was assessed, and
a second PDT
treatment was offered for individuals with an incomplete response to the first
PDT. All patients
were scored at 6 months after the first treatment, and a complete response
rate of 63% was found.
It is evident from the above that this is a time-consuming treatment both for
the patients
and for the gynaecologists. The patients will have to visit the gynaecologist
to have the
formulation applied, they then have to stay supine for 3-5 hours and then to
visit the
gynaecologist again for illumination. In addition, many of the patients who
did not respond to the
first treatment and had to go through the procedure once more.
The overall conclusion from these studies is that there is room for
improvement in the
clinical treatment efficacy of PDT in treating HPV and cervical cellular
abnormalities.
Furthermore, the procedure is time-consuming both for the patients as well as
for the hospital
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-3-
personnel. Similarly, there is room for improvement in the treatment of other
conditions affecting
the female reproductive tract and in the treatment of conditions affecting
other orifices.
There are several patent documents describing various devices for vaginal use,
cervical
drug delivery or photo-related diagnosis or therapy.
US 2008/0065003 discloses a LED-based cervical PDT device comprising an
illumination
head to be inserted into the cervical region. An LED array is either placed
within the illumination
head or in a hand piece connected to the head via a light guide. The device is
connected to an
external power supply and the light emitted by the LEDs is directed onto the
cervix by a. spherical
reflector within the illumination head.
GB 2370992 discloses an LED PDT device for treatment of the cervix. This
consists of a
head portion containing an LED array which is shaped for insertion through the
vagina to fit
closely over the opening of the cervix. The head portion is connected to a
hand piece via a hollow
stem, through which air and power are supplied from an external air and power
supply to the LED
array. The device is clamped into position for the duration of the treatment.
As will be appreciated, both of these devices require operation by a medical
practitioner
and so will normally be used within a medical institution, such as a hospital
or GP surgery. The
patient must remain still during the length of the illumination, which is
inconvenient and limits
the practical length of each treatment session.
In addition, the photosensitizer must be applied to the cervical area prior to
use of the
device. It is usual with current methods for the patient to wait several hours
between application
of the photosensitizer/ precursor and illumination.
PDT is today not a clinically valuable method for therapy of CIN and other
diseases/conditions of the cervix. This is due to the ineffective results of
therapy, as outlined in
the above cited report. Thus, there is a need for improved methods for therapy
of the cervix organ
system.
Surprisingly, it has been found by the inventors of the present invention that
the use of a
specific device, in combination with a photosensitizer or precursor, improves
therapy of cervical
cancer and other cervical diseases, lesions and conditions, especially those
diseases, lesions and
conditions caused by HPV infection. Similar improvements can be made in
connection with
photodynamic treatment of other conditions affecting the female reproductive
tract like for
instance vulvar intraepithelial neoplasia (VIN) or vulvar carcinomas. Further,
similar
improvements can be made in connection with PDT of cancerous or precancerous
conditions or
lesions of any other orifice of the human or animal body.
According to one aspect the present invention provides an irradiation device
for insertion
into an orifice of the body for providing photodynamic therapy or diagnosis,
the device
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-4-
comprising: a housing adapted to be fully inserted and secured in the orifice,
the housing
enclosing an LED lamp system and a power source for powering the LED lamp
system, wherein
the device is independently operational while located in the orifice.
Unlike prior art devices, the device of the present invention does not require
the patient to
remain at a medical facility during treatment. Rather, use of the device will
often imply only one
visit to the medical facility, after which the patient is free to leave.
Prolonged ongoing treatment
can occur while the patient continues with his or her normal daily activities.
This is because the device is adapted to be fully inserted and secured in the
orifice and
does not require connection to an external power supply or light source during
operation. By
"independently operable" it is meant that the device can provide illumination
for PDT without
concurrent connection to any external device. The device is hence fully self-
contained and forms
an enclosed unit including both the light source and the power supply required
for photodynamic
procedures.
As well as increasing the comfort and minimising disruption to the patient,
another
advantage of the present invention is that illumination can occur is
preferably carried out at very
low fluence rates. Fluence rate, F, refers to the radiant power incident on a
unit area and is
measured in units of W/cm2. Illumination with low fluence rates (e.g. 10
mW/cm2) requires that
the illumination will have to occur over a relatively long time period, e.g.
many hours, in order to
achieve the desired light dose necessary to achieve a therapeutic effect, and
hence is impossible in
a clinical (hospital) situation. However, illumination using low fluence rates
is known to strongly
reduce the patient discomfort (pain) during illumination, and may also improve
the PDT effect by
allowing a continuous build-up of endogenous porphyrins (from precursors) and
to prevent
oxygen depletion during illumination (S. Jacques et al., "PDT with ALA/PPIX is
enhanced by
prolonged light exposure putatively by targeting mitochondria", SPIE
Proceedings Vol. 2972,
"Optical Methods for Tumor Treatment and Detection", ed. T. Dougherty, San
Jose, February
1997, and M. Seshadri et al., Clin Cancer Res 14(9), 2796-2805 (2008)).
The device is therefore not only more "patient friendly", it can also increase
the efficacy of
the treatment.
The shape of the housing can vary, but is generally designed so that it
comfortably fits
within the orifice and remains in place independent of the patient's physical
activity. Where the
orifice of interest is the female reproductive tract, suitable shapes for the
outer portion of the
housing can for example be similar to the shapes of some contraceptive devices
used to prevent
pregnancy, such as FemCap and other similar devices intended for blocking
sperm from
entering the uterus. For other orifices, other suitable shapes and structures
can be utilised, for
example based on shapes known for use as suppositories and/or pharmaceutical
pessaries.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-5-
Although the present invention has been created with the treatment of human
patients in
mind, it is also possible for the device to be used in the treatment of other
animals. Therefore the
shape of the housing will be dependent on the orifice where treatment is
required and on the
anatomical structure of the animal on which the device is intended for use.
The device can comprise a slim housing, which the walls of the orifice will
envelope and
hold in place. When the device is for vaginal use the housing may, for
example, be similar in size
and shape to a tampon. The outer surface of the housing may be textured to
improve the grip of
the device. A textured surface can also be of benefit in providing a surface
for the delivery of
drugs to the area of the body that requires treatment.
To ensure a comfortable and effective treatment for each patient, devices of
different sizes
and/or shapes may be made available. For example, in the case of treatment of
the cervix devices
of three size may be provided for (i) patients that have not been pregnant,
(ii) patients that have
had a pregnancy but not carried to term and (iii) patients who have given
birth.
For some orifices, for example the rectum, a simple'torpedo' shape will enable
the device
to be inserted and secured. However, for other applications additional
features may be present in
order to ensure that the device is securely held within the orifice during
use. Hence, for vaginal
use the housing preferably comprises a flexible outer portion that can adjust
its shape to form a
secure fit with the vaginal walls and enables the device to be used within
many different shapes
and sizes of vagina. The flexible outer portion also helps to decrease the
risk of slipping or
misalignment of the device over an extended treatment period, during which the
patient may be
physically active. A similar outer portion may be used for a device intended
for insertion in other
orifices, if required.
For insertion into the ear or nose the device may be shaped based on known
designs for
ear or nose plugs.
The flexible outer portion can be formed from any material capable of
adjusting its shape.
For example, the flexible portion may be formed of an expandable, compressible
or deformable
material. A housing at least partially comprised of deformable material could
adjust its shape
during insertion to conform to the diameter of the orifice. Alternatively an
expandable material
could be used such that, after insertion, the outer portion of the housing
expands to firmly grip the
walls of the orifice. The expansion could be initiated through body heat,
exposure to fluid,
removal from a delivery device/instrument etc.
Preferably however the flexible outer portion is formed of a resilient
material. This
enables the shape of the flexible portion to be altered while also providing a
biasing outwards
force to hold the device in place. In order to achieve this effect the outer
diameter of the outer
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-6-
portion should be sized such that this must be reduced in order to insert the
device into the orifice.
The outer portion will then provide an outwards force to the walls of the
orifice.
The resilient material can be any resilient material commonly used in medical
devices; for
example rubber, latex, silicone or other natural, semi-synthetic or synthetic
polymers or
copolymers.
The flexible outer portion can be any shape which is capable of creating a
secure fit with
the walls of the orifice. For example, the flexible outer portion may be
provided in the form of a
number of discrete legs, ridges or other protrusions radially and/or
longitudinally spaced about
and extending outward from the housing. In other embodiments the flexible
outer portion may
form a continuous outer surface of the housing. This surface could either form
the whole or a part
of the exterior of the housing. For example the outer portion may be a disk or
cup-shaped section
found at either the front or rear of the device, or a covering which extends
over the entire length
of the housing.
In a preferred embodiment the flexible outer portion forms a continuous
surface which
tapers outwards towards the rear end of the device i.e. the end of the device
which, in use, is
closest to the entrance of the orifice. For example the outer portion can be
approximately
frustoconical in shape.
Although it is only necessary for an outer portion of the housing to be
flexible, in certain
preferred embodiments the entire housing is flexible. Creating a device having
a flexible housing
increases the comfort of the device and eases construction as only a single
material is required.
Preferably the housing comprises a treatment surface, the LED system being
arranged to
emit radiation from the treatment surface. The device can be arranged to
provide irradiation to the
walls of the orifice, in which case the treatment surface may be an outer
circumferential surface of
the housing. The treatment surface preferably has a size and or shape selected
for complimentary
fit with the treatment area, and is preferably sized to confront the entire
area where PDT is
required. The LED lamp system and treatment surface are preferably arranged
such that radiation
is emitted toward the treatment area at sufficient proximity and intensity to
achieve the desired
treatment effect.
The device may be arranged to provide irradiation to a particular area of the
inside of the
orifice. Thus, the device may include a treatment surface arranged to direct
and/or focus
illumination onto a particular area of the inside of the orifice when the
device is in use. In one
preferred embodiment the device is adapted for use in PDT of the cervix.
Therefore, preferably
the treatment surface is shaped so as to cover, in use, the opening of the
cervix. In this way, when
the device is correctly inserted into the vagina the treatment surface will
cover the opening of the
cervix and hence enable the emitted light to irradiate the cervical area.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-7-
The size of this treatment surface should be such that it fits over the entire
portio of the
uterine cervix, e.g. 20-50 mm in diameter, more preferably 20-35 mm in
diameter and most
preferably 22-30 mm in diameter.
Preferably, the treatment surface is at least partially transparent so as to
allow light from
the LED to pass through the surface to provide the required PDT treatment or
diagnosis. In some
embodiments the treatment surface may be fully transparent to light having the
wavelengths
required for PDT treatment and being emitted by the at least one LED. However,
preferably the
material of the treatment surface and/or other material between the treatment
surface and the light
emitting portion(s) of the LED lamp system is arranged to diffuse the light,
thereby enabling an
even distribution of light from a number of LEDs. In one embodiment, a
transparent material is
used to form both the housing around the LED lamp system and also the
treatment surface,
thereby acting as both a housing for the lamp system and a diffuser for the
light. In an alternative
embodiment, a transparent material is used to form the treatment surface while
a non transparent
material is used to form the housing. This will ensure that only the area in
need of treatment is
illuminated while other areas which get in contact with the device are not
subjected to irradiation.
Preferably, a transparent silicone is used as a material for the treatment
surface which acts as a
diffuser for the emitted light.
In some preferred embodiments the at least one LED may be positioned on or
extend out
of the treatment surface. In such embodiments it is not necessary for the
light to pass through the
treatment surface and hence no constraints are placed on its opacity.
In one preferred embodiment the treatment surface is concave. This can assist
in directing
the emitted light towards a treatment area, such as the cervix.
In embodiments designed for providing irradiation to the cervix, the device
comprises a
protrusion which extends from the treatment surface. Preferably this
protrusion forms a
cylindrical tube. This can be used both to assist in the correct positioning
of the device within the
vagina and also to direct light to the cervical canal. In the latter case the
tube acts as a light tube.
Preferably the flexible outer portion is located to the rear of the treatment
surface. This
prevents any interference with the radiation treatment. In preferred
embodiments in which the
outer portion is a continuous surface the outer portion can extend from the
treatment surface
towards to rear of the device, tapering outwards such that the widest section
of the outer portion is
located rearwards of the treatment surface.
The device comprises a LED lamp system which is capable of independent
operation
while the device is located within the orifice.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
The lamp system may comprise one LED or preferably an array of LEDs. A
particularly
preferred LED array for PCT of cervix comprises 3-15 LEDs. The term "LED" is
intended to
cover any form of light emitting diode, for example OLEDs (organic light
emitting diode).
The energy consumption per unit time of the LED lamp system should be such
that the
heating of tissue does not result in undue discomfort or damage to the
patient. The irradiation will
in general be applied at a dose level of 10 to 200 J/cm2, for example at 50
J/cm2. The LED lamp
system is therefore preferably arranged to provide, in operation, a fluence
rate in the range of 0.5
-100 mW/cm2, and most preferably in the range of 1 - 10 mW/cm2. This low
fluence rate results
in the total dose being administered over a relatively long time period, e.g.
several hours. As
mentioned above this is beneficial both in terms of reduced discomfort to the
patient and in the
efficacy of the treatment.
The wavelength of light used for radiation may be selected to achieve an
efficacious
photodynamic effect and hence the LEDs are selected for their ability to emit
wavelengths of light
suitable for this effect. In one preferred embodiment the at least one LED
emits, in use, light
having wavelengths in the range of 300-800 nm, for example, the range 500-700
nm has been
found to be particularly effective. It can be particularly important to
include the wavelengths 630
and 690 nm. Therefore preferably the at least one LED emits, in use, light
having wavelengths in
the range of 630-690 nm. In a most preferred embodiment, especially if the
device is used
together with a composition comprising a photosensitizer precusor selected
from 5-aminolevulinic
acid or a derivative, e.g. an ester thereof, red light (600 - 670 nm) is used
since light at this
wavelength is known to penetrate well into tissue. In some embodiments the LED
lamp system
comprises filters to ensure that only light within a certain wavelength range,
such as those
mentioned above, is emitted from the device. The treatment surface may be
designed such that
only light having these preferred wavelengths is transmitted.
The power source preferably comprises one or more batteries. The batteries
should
preferably operate via electrochemical reactions using chemicals that are not
too toxic for the
patient should the device break or leak while within the body. Suitable
batteries include lithium
batteries or equivalent of sufficient capacity which may also be stored for up
to 10 years. For
example a 1/2 AA size LiMnO2 battery may be used. The slow loss of charge and
small size of
lithium ion batteries makes them particularly suited for use- as the power
supply for the device. In
order to increase the safety of the device, it is preferable that the power
source is sealed within the
housing. By sealed it is meant that the housing is fluid tight in use to
prevent fluids leaking into
or out of the device.
At its most basic the lamp system can simply comprise electrical connections
for the
power supply and an LED or LEDs. With this arrangement, immediately prior to
insertion of the
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-9-
device the lamp system would be activated to switch on the one or more LEDs.
The device would
then be inserted into the orifice where the LED(s) will illuminate the
treatment area until the
device is removed or the power supply is depleted.
Activation of the lamp system may be triggered by a switch. In order to allow
the device
to be maintained sterile and to keep the power source and other elements of
the device enclosed,
the switch is preferably enclosed within the housing and arranged to be
operated whilst sealed
within the housing. The switch may be a mechanical switch located beneath a
flexible part of the
housing, with operation of the switch being permitted by the resilience of the
flexible part.
Alternatively the switch may be operated by means of an electrical or magnetic
field transmitted
through the housing. A magnetically operated switch may be implemented by the
use of a magnet
outside the housing to hold a 'normally closed' reed switch open. When the
magnet is removed
the reed switch will close and this can be used to activate the device.
In a simple system using just a power source and LED it is hard to control the
dosage
level, as the precise life and power output of the power supply will vary. In
addition the
illumination provided by the LED array will be constant. In order to avoid
unacceptable heating
of tissue, low intensity light is preferably used and it may also be
beneficial for the device to be
able to provide pulsed light.
Therefore preferably the lamp system further comprises a control circuit, such
as a
microcontroller or microprocessor, for regulating the irradiation provided by
the at least one LED.
The control circuit of the lamp system may be activated by a switch as
described above. In a
preferred embodiment the control circuit comprises a timer. The lamp system
can then be
programmed to begin illumination at a pre-determined time interval after
activation. This ensures
that sufficient time has passed from activation to the start of illumination.
For example, in order
to allow the absorption or build up of porphyrins a certain time is required
after application of a
photosensitiser or precursor drug: The length of illumination can also be
strictly controlled as the
control circuit can be arranged to switch off illumination after a pre-
determined dosage time has
elapsed. To allow further build-up of endogenous photo sensitizers (from
precursors) after the first
illumination, the device may repeat the illumination (re-PDT) after a certain
period of time, e.g. 3
hours.
In addition the control circuit may be arranged to provide pulsed
illumination. This can be
achieved by providing a function generator within a microprocessor. As
mentioned above, pulsed
light is advantageous in ensuring that no unacceptable heating of tissue
occurs. In addition,
providing intervals in illumination enhances tissue oxygenation and the effect
of PDT. Further it
allows for the re-accumulation of endogenous porphyrins in surviving cells
that can be, treated
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-10-
with repeated illuminations. The frequency and length of the pulses can be
chosen according to
the requirements of the treatment regime and set within the control circuit.
In one embodiment, the control circuit can be programmed by the user. This
enables the
length, strength and illumination pattern to be adjusted to suit individual
treatments. Suitable re-
writable memory forms include EPROM, EEPROM, flash etc. However, the control
circuit
memory is preferably read only (ROM) and programmed at the time of
manufacture.
Access to the control circuit could be achieved by means of a user interface
on the device.
By answering a series of questions the user can set the initial delay period,
dosage duration,
number and length of light pulses etc. The interface may be integral with the
device. Thus, it
may comprise small buttons that may be pressed with a suitable tool or reed
switches. Each
button or switch may activate a given pre-set condition such as light dose,
intensity, pulsed/steady
light, etc.
It is important that all the electrical components of the lamp system
and.power source are
sealed within or to the housing during use. Therefore the control circuit
should preferably be
sealed within the housing. As mentioned previously the LED(s) could be
positioned such that
these protrude from the housing. However, preferably the LED lamp system is
entirely sealed
within the housing during use.
In some embodiments the user interface may be accessible through a flexible
area of the
housing. Alternatively the housing may comprise an sealable opening which
provides access to
the interface.
The provision of a user interface however increases the size of the lamp
system, which
may be undesirable in certain applications. Therefore, alternatively, the
control circuit may
comprise a receiver for connection to a remote terminal. In this way specific
program commands
can be communicated from the remote terminal, e.g. a computer, to the control
circuit.
In some embodiments the receiver comprises an input port adapted for
connection to a
cable. In such embodiments the input port is suitably shaped to receive, for
example, a USBor
other male connector.
The input port must be sealed during use. Therefore the housing may comprise a
plug for
insertion into the port. Alternatively the housing may consist of two
components which can be
connected by means of, for example, screw threads, push or snap fit connection
or bayonet fitting.
The connection comprises seals in order to ensure that the control circuit is
sealed within the
housing during use.
Alternatively the program commands may be transmitted to the device by means
of a
wireless connection. For example, the receiver may be an infra-red or radio
wave receiver. This
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-11-
has the advantage that a physical input port is not necessary and instead the
control circuit can be
permanently sealed within the housing.
Preferably the control circuit further comprises a feedback system. This
enables the
control circuit to make adjustments in the treatment program to account for
deviations in expected
LED performance.
For example, the feedback system may comprise a light monitor or other direct
or indirect
monitor to measure the light dose that has been given to the patient. In such
systems the control
circuit may be programmed to switch off the LED(s) after a pre-determined
dosage has been
reached rather than a pre-determined time.
Alternatively the dosimeter may override the timer in the event that the LEDs
do not
operate as expected. For example, if the power supply is faulty the output of
the LEDs may be
reduced. Therefore it will be necessary to continue illumination beyond the
pre-determined time
in order to obtain a complete dose. Conversely if the power output of the LEDs
is stronger than
anticipated the illumination can be stopped ahead of the pre-determined time
interval, or the
duration of each pulse can be shortened to prevent overheating of tissue.
Another optional feature of the control circuit is one or more performance
indicator lights
for informing a user whether the device has operated correctly or whether a
fault has occurred.
The control circuit may be arranged to provide a signal to the user when
treatment is complete to
indicate that the device can be removed. For example an acoustic and/or visual
signal may be
provided, such as an alarm sound and/or a light signal. Alternatively or in
addition, a vibration
could be used as the signal to indicate the end of the treatment. Typically
the patient would be
informed of the length of the treatment and so the signal can be used to
confirm an expected end
of the treatment and hence need not be overly intrusive.
Advantageously, as the control circuit may be used to turn off the LEDs at the
end of the
treatment cycle there is no great ill effect for the patient if the device
remains inserted for longer
than the treatment time. However, it is expected that patients will wish to
know when treatment
has ended and the device can be removed.
Preferably some or all of the above mentioned features of the control circuit
are contained
in a microprocessor.
Preferably the device further comprises a lens system arranged to provide
homogenous
illumination over the treatment area. The treatment surface may act as the
lens system. For
example, this surface may be formed of silicone or another material comprising
surface elements
for diffusing the light emitted by the LED(s).
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
- 12-
In use the device is preferably placed into the orifice by a doctor, a nurse
or another person
with experience or education within relevant fields. However, patients might
in some situations
choose to insert the device themselves.
In one preferred embodiment the device comprises a handle at its rear end. The
handle
can be used by the patient or medical practitioner to firmly grip the device
during insertion and
removal.
The handle may be an elongate arm extending from the housing of the device. In
a
preferred embodiment however the handle is arcuate in shape as smooth edges
will prevent the
possibility of discomfort or damage to the patient. In some preferred
embodiments, the arcuate
handle is attached to the device at two or more points on the flexible outer
portion. This is
beneficial as, when the handle is grasped and pulled, the flexible outer
portion will be pulled
inwards, thus easing removal of the device. A similar effect can be achieved
by attaching a string
or cord to at least two positions on the outer portion, although this latter
embodiment will not
assist in insertion.
Therefore preferably the device further comprises a removal mechanism attached
at two or
more positions to the flexible outer portion and comprising a central gripping
portion.
Another option is for the device to be placed (and removed) using a specific
instrument,
such as a pair of tweezers.
Advantageously, the device is designed for a single-use and for disposal after
that single
use. Preferably, the device includes one or more features that promote single-
use and/or prevent
repeat use. For example, the power source may be arranged to provide power
that is only
sufficient for a single-use, i.e. such that the power source is depleted after
the required treatment
is complete. The power source may be arranged so as not to be re-charged,
and/or the control.
circuit may lack access to re-charge the power source. The control circuit may
be arranged to
prevent re-use by means of features of its programming and/or it may include a
deactivation
mechanism that destroys circuitry or software when triggered. To prevent
patient interference
when in use, the control circuit may also be arranged to selectively
deactivate if interference is
detected. By enforcing single use patient safety is improved and a strict
control of sterility of the
device is ensured.
The device of the present invention can be used to provide PDT according to
the following
method. Firstly a composition comprising a photosensitizer or precursor
thereof is applied to the
area to be treated by a physician, where applicable by using a specialised
applicator, or the area
of interest is treated by means of a systematically acting drug. Such a
systematically acting drug
may be supplied intravenously or orally, for example. The programmed device is
then switched
on and inserted. The patient can then immediately leave the medical facility
and continue their
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
- 13 -
normal daily routine while the treatment area is receiving illumination from
the device. In this
way treatment can occur over a prolonged period of time without inconvenience
to the patient.
This allows a low fluence rate to be used, increasing the efficacy of the
treatment. After the
treatment is complete the patients can either return to the medical
institution for removal of the
device or remove it themselves. The device can either be discarded or returned
to the medical
institution for disposal.
In a preferred embodiment the device of the present invention further
comprises a drug
delivery system. The drug delivery system may comprise a drug carrying area on
the housing,
such as a drug carrying area on the treatment surface. This might be a
textured surface for
carrying a composition of photosensitizer or precursor or the treatment
surface itself without any
further modifications may act as a drug delivering system. Alternatively, the
drug delivery system
may comprise a reservoir for housing a composition comprising a
photosensitizer or precursor
thereof (hereinafter "composition").
The advantage of this embodiment of the present invention is that the patient
need not wait
at the hospital for several hours between application of the composition and
illumination, as is
normal in existing PDT procedures. The device may automatically perform the
illumination
either immediately upon application or preferably at a later time. In
addition, only one invasive
procedure is required.
Optionally the drug delivery system further comprises a physical, mechanical
or electrical
system related to delivery. Such an optional system may include, for example,
filters,
membranes, one or more reservoirs arranged to deliver the photosensitizer or
precursor based
upon a preset plan for drug delivery or based on physical conditions, such as
for example pH,
osmolality, temperature, pressure, water content in the surroundings. However,
the simplest and
in most cases the most preferred drug delivery system is just a single drug
carrying area for
housing the composition, and in a most preferred embodiment, the drug delivery
system is the
treatment surface itself.
In this preferred embodiment the method of use is similar to that described
above except
that the composition is not applied to the treatment area in a separate
procedure. Instead the
composition is applied to the drug carrying area, e.g. the treatment surface,
and is hence applied to
the body upon insertion of the device into the orifice. Illumination is then
conducted as described
above.
The composition can be supplied together with the device. In such instances
the drug
delivery system, i.e. drug carrying area or reservoir, preferably treatment
surface, may be supplied
with a cover, such as a foil or cap, to seal the composition within the device
until use. Prior to
insertion the cover is removed so that the composition can be released.
Alternatively the device
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-14-
can be supplied separately from the composition. This enables the physician to
choose the
optimal composition for a particular-case and add this to the drug delivery
system, i.e. drug
carrying area or reservoir, preferably treatment surface, prior to insertion.
The composition to be used with the device, whether in a pre-filled device or
applied to
the device before use or applied to the treatment area separately, may
comprise any suitable
photosensitizer or precursor of a photosensitizer.
A range of photosensitizers are known in the scientific literature. As
discussed above, one
type of such compounds are compounds that per se are toxic to target cells or
species or have light
emitting properties when exposed to light. Such compounds have relatively
large molecular
weights and are often complex molecules like phthalocyanines, chlorines,
porphyrins or
psoralens. Another type of photosensitizers are compounds that not per se are
toxic or light
emitting, but form such active compounds in vivo. Such compounds - referred to
herein as
precursors - are typically 5-aminolevulinic acid (5-ALA) and derivatives of 5-
ALA, like 5-ALA
esters. Either type of compound can be used or supplied with the present
device.
5-aminolevulinic acid (5-ALA) and its derivatives are amongst the most
clinically. useful
precursors of photosensitizers known in the art. These compounds are converted
in the body to
protoporphyrin IX (PpIX), which is a photosensitizer that absorbs light and in
contact with
oxygen generates singlet oxygen. Singlet oxygen is extremely reactive and
reacts fast with various
cellular biomolecules resulting in cell death.
5-ALA and its derivatives are widely known and used in methods of photodynamic
therapy (PDT) for the treatment of various abnormalities or disorders of the
skin or other
epithelial organs or mucosa, especially cancers or pre-cancerous lesions, as
well as certain non-
malignant lesions, e.g. skin diseases such as psoriasis, actinic keratosis
(AK) and acne. 5-ALA
(Levulan , Dusa) and 5-ALA methyl ester (Metvix ,Galderma, Switzerland) are
commercial
therapeutic products for PDT treatment of actinic keratosis and basal cell
carcinoma.
The use of 5-ALA and derivatives thereof, e.g. 5-ALA esters in PDT is well
known in the
scientific and patent literature (see, for example, WO 2006/051269, WO
2005/092838, WO
03/011265, WO 02/09690, WO 02/10120 and US 6034267). All such derivatives of 5-
ALA and
their pharmaceutically acceptable salts are suitable for use with the device
herein described.
Esters of 5-aminolevulinic acid and N-substituted derivatives thereof are
preferred
precursors in a composition for use with the invention. Those compounds in
which the 5-amino
group is unsubstituted, i.e. the ALA esters, are particularly preferred. Such
compounds are
generally known and described in the literature (see, for example, WO 96/28412
and WO
02/10120 to Photocure ASA).
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-15-
Esters of 5-aminolevulinic acid with substituted or unsubstituted, preferably
substituted,
alkanols, i.e. alkyl esters or, more preferably, substituted alkyl esters, are
especially preferred
precursors in a composition for use with the invention.
Examples of such precursors include those of formula (I) and pharmaceutically
acceptable
salts thereof:
R22N-CH2000H2-CH2CO-OR' (I)
wherein
R' represents a substituted or unsubstituted alkyl group; and
R2 each independently represents a hydrogen atom or a group R1
As used herein, the term "alkyl", unless stated otherwise, includes any long
or short chain,
cyclic, straight-chained or branched saturated or unsaturated aliphatic
hydrocarbon group. The
unsaturated alkyl groups may be mono- or polyunsaturated and include both
alkenyl and alkynyl
groups. Unless stated otherwise, such alkyl groups may contain up to 40 carbon
atoms. However,
alkyl groups containing up to 30 carbon atoms, preferably up to 10,
particularly preferably up to
8, especially preferably up to 6 carbon atoms are preferred.
In compounds of formula I, the R' groups are substituted or unsubstituted
alkyl groups. If
R' is a substituted alkyl group, one or more substituents are either attached
to the alkyl group
and/or interrupt the alkyl group. Suitable substituents that are ,attached to
the alkyl group are those
selected from: hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl,
nitro, oxo, fluoro, -
SR3, -NR32 and -PR32, wherein R3 is a hydrogen atom or a C1_6 alkyl group.
Suitable substituents
that interrupted the alkyl group are those selected from: -0-, -NR3-, -S- or -
PR3..
If R' is a substituted alkyl group, one or more aryl substituents, i.e. aryl
groups, preferably
one aryl group, are preferred.
As used herein, the term "aryl group" denotes an aromatic group which may or
may not
contain heteroatoms like nitrogen, oxygen or sulphur. Aryl groups which do not
contain
heteroatoms are preferred. Preferred aryl groups comprise up to 20 carbon
atoms, more preferably
up to 12 carbon atoms, for example, 10 or 6 carbon atoms. Preferred
embodiments of aryl groups
are phenyl and napthyl, especially phenyl. Further, the aryl group may
optionally be substituted
by one or more, more preferably one or two, substituents. Preferably, the aryl
group is substituted
at the meta or para position, most preferably the para position. Suitable
substituents include halo
alkyl, e.g. trifluoromethyl, alkoxy, preferably alkoxy groups containing 1 to
6 carbon atoms, halo,
e.g. iodo, bromo, chloro or fluoro, preferably chloro and fluoro, nitro and
C1_6 alkyl, preferably
C14 alkyl. Preferred C1-6 alkyl groups include methyl, isopropyl and t-butyl,
particularly methyl.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-16-
Particularly preferred aryl substituents are chloro and nitro. However, still
more preferably the
aryl group is unsubstituted.
Preferred such R' groups are benzyl, 4-isopropylbenzyl, 4-methylbenzyl, 2-
methylbenzyl,
3-methylbenzyl, 4-[t-butyl]benzyl, 4-[trifluoromethyl]benzyl, 4-methoxybenzyl,
3,4-[di-
chloro]benzyl, 4-chlorobenzyl, 4-fluorobenzyl, 2-fluorobenzyl, 3-fluorobenzyl,
2,3,4,5,6-
pentafluorobenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2-phenylethyl, 4-phenylbutyl,
3-pyridinyl-
methyl, 4-diphenyl-methyl and benzyl-5-[(1-acetyloxyethoxy)-carbonyl]. More
preferred such RI
groups are benzyl, 4-isopropylbenzyl , 4-methylbenzyl 4-nitrobenzyl and 4-
chlorobenzyl. Most
preferred is benzyl.
If R' is a substituted alkyl group, one or more oxo substituents are
preferred. Preferably,
such groups are straight-chained C4_12 alkyl groups which are substituted by
one, two or three oxo
groups. Examples of such groups include 3,6-dioxa-l-octyl and 3,6,9-trioxa-l-
decyl.
If R' is an unsubstituted alkyl group, R' groups that are saturated straight-
chained or
branched alkyl groups are preferred. If R' is a saturated straight-chained
alkyl group, C1-1o
straight-chained alkyl group are preferred. Representative examples of
suitable straight-chained
alkyl groups include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and n-
octyl. Particularly
preferred are C1_6 straight-chained alkyl group, most particularly preferred
methyl and n-hexyl. If
R' is a saturated branched alkyl group, such branched alkyl groups preferably
consists of a stem of
4 to 8, preferably 5 to 8 straight-chained carbon atoms which is branched by
one or more C1_6
alkyl groups, preferably C1_2 alkyl groups. Examples of such saturated
branched alkyl groups
include 2-methylpentyl, 4-methylpentyl, 1-ethylbutyl and 3,3-dimethyl-l-butyl.
In compounds of formula I, each R2 independently represents a hydrogen atom or
a group
R'. Particularly preferred for use in the invention are those compounds of
formula I in which at
least one R2 represents a hydrogen atom. In especially preferred compounds
each R2 represents a
hydrogen atom.
The most preferred precursors to be used in a composition together with the
devices
according to the invention are compounds of formula I and pharmaceutically
acceptable salts
thereof, wherein R' is C1-C6 alkyl, e.g. hexyl, more preferably straight chain
C1-C6 alkyl, e.g. n-
hexyl and both R2 represent hydrogen, i.e. 5-ALA hexyl ester and
pharmaceutically acceptable
salts thereof, preferably the HCl salts. The most preferred precursor is 5-ALA
hexyl ester and the
most preferred pharmaceutically acceptable salt of 5-ALA hexyl ester is the
HCl salt.
The composition comprising the photosensitizer or precursor to be used
together with the
current device can be any type of pharmaceutical formulation and may be
prepared by any
conventional procedure available in the art (see WO 02/10120 to Photocure
ASA). For example,
esters of 5-ALA may be prepared by reaction of 5-ALA with the appropriate
alcohol in the
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
- 17-
presence of base. Alternatively compounds for use in the invention may be
available
commercially (e.g. from Photocure ASA, Norway).
Preferred formulations are liquids (aqueous and non-aqueous), solids such as
dusting
powder, tablets or suppositories, semi-solids such as creams, ointments, gels
or pastes, foam
formulations or other expandable formulations (for example based on heating to
body-
temperature) and formulations/systems similar to patches. The components in
the composition are
the same components found in pharmaceutical products on the market, and a
listing of such
components can be found in handbooks of pharmaceutical excipients.
It is important that the formulation is a such that the composition is
absorbed completely
into the tissue to be treated or is transparent in order not to interfere with
the illumination. As
noted above, it is also possible to make use of compositions that are applied
systematically, for
example drugs that are given to the patient intravenously.
Viewed from another aspect. the present invention provides a method of
photodynamic
therapy of a treatment area within an orifice of the body, the method
comprising: applying a
composition comprising a photosensitizer or precursor to the treatment area
and inserting an
irradiation device according to the present invention into the orifice, such
that the LED lamp
system of the irradiation device operates to provide illumination to the
treatment area.
The method may include a step of selecting a device of suitable size and/or
shape. The
device may be selected firstly to suit the orifice concerned, and secondly to
suit different patient
conditions. For example, a device for treatment of the cervix would preferably
be selected from a
range of sizes depending on the patient's history of pregnancy.
The composition may be applied to the treatment area prior to insertion of the
device, and
this may be done by directly applying the composition, where applicable by
using a suitable
applicator, or by means of a systematically applied drug, for example a drug
introduced
intravenously into the patient. In an alternative preferred embodiment the
composition is supplied
via a drug delivery system of the device such that the steps of application of
the composition and
insertion of the device occur simultaneously. The drug delivery system may
comprise a drug
carrying area or reservoir or may simply be the treatment surface of the
device, as discussed
above.
Preferably the lamp system provides a.dose level of 10 to 200 J/cm2, for
example 50
J/cm2. The lamp system may have features as discussed above.
The device can be provided separately from the composition or with the
composition
already contained within a drug delivery system. Alternatively the device
could be provided in
the form of a kit comprising the device and at least one composition for use
with the device.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-18-
The present device and method for photodynamic treatment may be combined with
other
therapeutic procedures, for example administration of other therapeutic drugs.
These therapeutic
drugs might be administered into the body prior to or together with placing
the device in the
orifice or might be administered through other routes of administration (e.g.
oral, intravascular or
dermal). Typically such drugs include hormones, antibacterial agents,
antifungal agents, antiviral
agents, anticancer agents or combination of such drugs.
Although some of the preferred features of the invention have been described
in relation to
providing PDT to the vagina and cervix, it will be appreciated that these
features device could
advantageously be included in devices for use in other body orifices, such as
devices for the
rectum, ear or nose, as discussed above. The present invention is not limited
as to the particular
orifice that it is to be used in, but instead the invention provides a device
and method that can be
beneficially used in the treatment of various conditions in different
orifices.
Several preferred embodiments of the present invention will now be described,
by way of
example only, with reference to the accompanying drawings in which:
FIGs 1 A and 1 B show a perspective view and cross-section respectively of a
first
preferred embodiment of an irradiation device;
FIGs 2A and 2B show a perspective view and cross-section respectively of a
second
preferred embodiment of an irradiation device;
FIGs 3A and 3B show a perspective view and cross-section respectively of a
third
preferred embodiment;
FIG 4 shows a schematic diagram of a control circuit for use in the
irradiation device of
the preferred embodiments;
FIGs 5A and 5B show an isometric perspective view and cross-section of a
fourth
preferred embodiment of an irradiation device;
FIGs 6A, 6B, 6C and 6D show a perspective view, side elevation, end elevation
and cross-
section view of a fifth preferred embodiment of an irradiation device; and
FIGs 7A, 7B, 7C and 7D show a perspective view, side elevation, end elevation
and cross-
section view of a fifth preferred embodiment of an irradiation device.
FIGs 1A and B show a first embodiment of an irradiation device 10 for
photodynamic
therapy. The device 10 of the first embodiment is arranged for use in
photodynamic treatment of
the cervix. The device 10 comprises a flexible. housing 1. The outer portion 7
of this housing is
approximately frustoconical in shape and tapers outwards from the front end of
the device to the
rear. The outer portion 7 is resilient such that in use this presses against
the walls of the vagina in
order to securely hold the device 10 in place.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-19-
Sealed within the housing I is a lamp system 12. This system 12 comprises an
array of
LEDs 5 and a control circuit 6. This control circuit 6 will be discussed in
more detail below. It
provides power to the LEDs 5 such that, in use, these will illuminate.the
cervix.
The front end of housing 1 forms a treatment surface 2. This treatment surface
2 is shaped
so as to cover, in use, the opening, of the cervix, thus ensuring that the
illumination from the LEDs
5 is directed on to the treatment area. Treatment surface 2 comprises a ring
shaped contact
surface 2a and a concave portion 2b. Typically the contact surface 2a has a
diameter of 20 to 50
mm.
In order to assist in the removal of the device 10, a string 4 is attached to
at least two
positions on the outer portion 7. When the string 4 is grasped and pulled, the
outer portion 7 is
drawn inwards, hence easing the removal of the device 10.
FIGs 2A and 2B show an alternative embodiment of the device 20, which is also
intended
for use in the treatment of the cervix. In this embodiment, the device 20
again comprises a
resilient outer portion 27 which is generally frustoconical in shape. In
addition, the treatment
surface 22 is again formed of a ring shaped contact surface 22a and a concave
portion 22b.
However, in this embodiment only the control circuit 26 is sealed within the
housing 21. The
LED array 25 protrudes into the concave portion 22b of contact surface 22.
Further, the device 20 comprises an arcuate handle 23 which extends from the
rear end of
the housing 21. Unlike the string used in the first embodiment, the handle 23
of device 20 can be
used to assist in both the insertion and removal of the device.
A third embodiment of the device 30 is shown in FIGs 3A and 3B. Once again,
the main
shape of the housing 31 and the outer portion 37 remains unchanged.
The device 30 is similar in design to that.of the device 10. Both the LED
array 35 and the
control circuit 36 are housed within housing 31 and a string 34 is provided to
assist in the removal
of the device 30.
However, two important differences exist. Firstly, a protrusion 38 extends
from the
treatment surface 32. This protrusion 38 forms a drug delivery system and
light tube through
which light from the LEDs 35 is directed. This protrusion 38 is shaped so as
to contact, in use,
the cervical canal. The tube allows the photosensitizer or precursor to be
delivered to the cervical
canal (endocervix) as well as the light from the LEDs 35 and therefore
increases the ability of the
device 30 to provide photodynamic therapy.
Further, the concave portion 32b of the treatment surface acts as a reservoir
within which a
treatment composition 39 can be housed. It can be seen that the concave
portions 2b, 22b of the
previous embodiments would also be suitable for housing this composition 39.
In this way, the
device of the present invention can also act as a drug delivery device. The
composition 39
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-20-
contains a photosensitizer or precursor suitable for photodynamic treatment or
diagnosis. By
placing this composition 39 within the device 10,20,30, the composition can be
applied to the
treatment area upon insertion of the device. In addition, delivery of the
composition to the
cervical canal can be obtained by also coating the protrusion 38 with the
composition before
inserting the device into the patient. In this way the patient need only
undergo one invasive
procedure before photodynamic treatment or diagnosis can be carried out.
A control circuit suitable for use in any of the preferred embodiments of the
irradiation
device is shown in FIG 4. This control circuit 40 takes power from lithium
batteries 41 which are
used to power the LED array 45. The control circuit 40 comprises a
microprocessor 42, which
controls the operation of the LED array 45.
For example, the microprocessor. 42 can comprise a timer and a memory into
which can be
programmed a dosage regime. The LED array 45 can therefore be operated to
illuminate the
treatment area for a predetermined length of time and can be arranged to
operate continuously or
provide pulsed illumination. In addition the control circuit 40 comprises a
light sensor 43. This
forms a feedback circuit which enables the microprocessor 42 to adjust the
operation of the LEDs
45 to ensure that any abnormalities or malfunction of the control circuit 40
do not affect the
dosage received by the patient.
Prior to the insertion of the device, a switch 46 is closed to begin operation
of the control
circuit 40. This may, for example, initiate timing of a "delay period", after
which the
microprocessor 42 will begin operation of the LED array 45 in accordance with
the programmed
regime. After a predetermined time, or upon completion of a certain light dose
(determined by
light sensor 43) the microprocessor 42 will switch off the LEDs 45. The device
can then be
removed. -
In modified embodiments the control circuit also comprises two operation
indicator lights
(not shown). These may comprise two LEDs, one of which is illuminated if the
device has
operated correctly and a second LED which is illuminated if any malfunction
has occurred;
combinations of lights may indicate specific faults. Alternatively only a
single operation indicator
light may be provided, which is illuminated upon completion of correct
operation of the device
and which remains unlit if any malfunction has occurred. The control circuit
may incorporate an
' 30 alarm device for providing an audible signal, and/or a vibration device
for providing a signal by
vibration.
This system alerts the patient and the medical practitioner if any malfunction
has occurred
which has prevented the patient from receiving the correct dosage. Signals
from the control
circuit can also indicate that the treatment has been completed successfully.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-21 -
FIGs 5A and 5B show a fourth embodiment of an irradiation device, and in this
embodiment the device is arranged for treatment of the walls of an orifice of
the human or animal
body. The orifice could be, for example, the vagina, rectum, ear or nose. The
particular size of
the device and the specific shape can be varied in accordance with the size
and shape of the
orifice.
The device includes a housing 51 that encloses an array of LEDs 54 and a power
supply
and control circuit 55. The housing 51 of the illustrated embodiment is an
elongate cylindrical
shape with a hemispherical end 52. This shape is a preferred shape for
insertion into the vagina
and rectum, for insertion into other orifices, a conical end (not shown) could
be used in place of
the hemispherical end 52. A smaller device would be used for insertion into
the nose and
typically the shape would be adjusted to be more conical. For insertion into
the ear a still smaller
size and a slimmer shape would be used. At the opposite end to the
hemispherical end 52 (or
optional conical end) the device has a loop 53 to aid insertion and removal
and to attach a string,
if required.
The elongate cylindrical portion of the housing 51 includes a treatment
surface about its
outer circumferential surface. The treatment surface will contact the inside
wall of the orifice in
order to provide illumination to a treatment area on the orifice wall. To this
end, the LED lamp
system includes an array of LEDs 54 located about the elongate cylindrical
portion beneath the
treatment surface. The LEDs 54 are arranged to provide illumination through a
cylindrical
treatment surface. In modified embodiments, LEDs may also be located
underneath a treatment
surface of the hemispherical or conical end portion of the device. The housing
51 is made of
transparent silicone, and this also forms the treatment surface which may also
act as a drug
delivery system. The transparent silicone acts as a lens that diffuses light
emitted from the LED
array and hence acts to evenly distribute the emitted light.
FIGs 6A, 6B, 6C and 6D show a fifth embodiment of an irradiation device 60 for
photodynamic therapy. Figure 6D is a cross-section along line A-A on Figure
6C. The device 60
of the fifth embodiment is arranged for use in photodynamic treatment of the
cervix and has a
housing 61 including an upper housing portion 61 a with features similar to
the first and second
embodiments, with the addition of a lower cylindrical housing portion 61b
extending beneath the
upper housing portion. The upper housing portion 61 a is flexible and includes
an outer portion 67
that is approximately frustoconical in shape and tapers outwards from the
front end of the device
60 to the rear. The outer portion 67 is resilient such that in use this
presses against the walls of
the vagina in order to securely hold the device 60 in place. The shape of the
upper housing
portion 61 a and its outer portion 67 can most clearly be seen in Figure 6D.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-22-
The LED lamp system 62 is sealed within the upper housing 61 a, and has
features similar
to the embodiments discussed above. The power supply for the lamp system is a
battery 68
enclosed within the cylindrical housing portion 61b. The battery is a 1/2 AA
size battery with the
cylindrical housing portion 61b formed relatively tightly around it. The
control circuit 69 is also
enclosed with the battery, and advantageously this takes the form of a PCB
with a diameter the
same as the battery diameter, for efficient use of space.
The front end of the upper housing 61 a forms a treatment surface 63, which is
a lens of
transparent material covering the LEDs of the LED lamp system 62. As with the
fourth
embodiment, this material can be a transparent silicone which also forms the
remainder of the
flexible housing of the device 60. An opaque white silicone over-moulding can
be used to cover
the sides of the upper housing portion 61 a, both about the outer portion 67
and also on the sides
within the outer portion 67, and to completely cover the cylindrical portion
61b. This white over-
moulding acts as a reflector for the lens of the treatment surface, and hides
internal parts in the
cylindrical portion, which would include the battery 68 and control circuit
69. In one
embodiment, the underside surface of the housing portion. 61 a may be of black
colour to protect
the vaginal mucosa which is not in need of treatment against the emitted
light.
The treatment surface 63 is shaped so as to cover, in use, the opening of the
cervix, thus
ensuring that the illumination from the LEDs is directed on to the treatment
area. Treatment
surface 63 comprises a contact surface 63a, which typically has a diameter of
22 to 30 mm. In a
preferred embodiment, said contact surface 63a acts as a drug delivery system,
i.e. drug carrying
area or reservoir and carries a photosensitizer or a precursor.
At the base of the cylindrical housing portion 61b a loop 64 is provided to
facilitate
insertion and removal of the device. A string can be attached to the loop 64,
if required.
Alternatively, the loop 64 is missing and a string is attached directly to at
least two portions on the
cylindrical housing portion 61b (not shown).
A sixth embodiment of the irradiation device 70, which is shown in FIGs 7A,
7B, 7C and
7D. Figure 7D is a cross-section along line B-B on Figure 7C. Irradiation
device 70 has a housing
71 consisting of an upper housing portion 71 a and a lower housing portion
71b, wherein the upper
housing portion 7.1 a is similar to the upper housing portion 61 a of the
device 60 of the fifth
embodiment. The upper portion 71 a hence includes a generally frustoconical
outer portion 77,
with a treatment surface 73 formed by a contact portion 73a and a concave area
within the
truncated top of the frustoconical portion 77. The outer portion 77 of the
sixth embodiment is
shorter than the outer portion 67 of the fifth embodiment, which represents an
alternative way of
forming the device, and it should be appreciated that both of the fifth and
the sixth embodiment
could be adapted to use either the shorter or longer brim, each of which have
different
CA 02748144 2011-06-22
WO 2010/078929 - 23 - PCT/EP2009/009037
characteristics and advantages. A loop 74 is provided in the sixth embodiment
in a similar
fashion to the fourth and fifth embodiments. Alternatively, the loop 74 is
missing and a string is
attached directly to at least two portions on the lower housing portion 71b
(not shown).
The lower cylindrical housing portion 61b of the sixth embodiment is replaced
by an
alternative lower housing portion 71 b, which takes the form of a generally
triangular prism with
its long axis extending across a diameter of the upper portion 71 a. The
triangular prism is
arranged to house a 1/2 size AA battery placed transversely across the device,
instead of
longitudinally in a cylindrical section as in the sixth embodiment. The edges
of the prism are
rounded for comfort. The control circuit 79 and LED lamp system 72 are.both
located above the
battery 78.
As with the fifth embodiment, the sixth embodiment can include a white over-
moulding to
direct light to the treatment surface 73.
As discussed above, with a device intended for treatment of the cervix it is
advantageous
to provide different sizes since it allows effective treatment for patients
with different histories of
pregnancy. With the fifth and sixth embodiment, these different sizes can be
realised by adjusting
the size of the upper portions 61 a, 71 a, as these portions act to secure the
device within the vagina
with the treatment surface placed against the cervix. The lower portion 61b,
71b, which houses
the power supply, can be manufactured in a single size, enabling a
standardised arranged to be
used for the battery 68, 78 and control circuitry 69, 79.
The photosensitising composition for the photodynamic therapy can be applied
to the
patient prior to insertion of the device, either directly to the surface of
the treatment area, or
systematically by intravenously or orally administered compositions.
Preferably, the composition
is applied to the treatment surface so that the photosensitising composition
is applied to the
patient during insertion of the device. With embodiments using a concave
treatment surface, a
photosensitive formulation may be placed within the concave area providing a
reservoir of the
formulation as discussed above. Alternatively, the material of the device may
be selected so that
the required photosensitive formulation will adhere to the treatment surface
sufficiently for
transfer to the patient and the formulation can then be simply applied in a
layer on the treatment
surface. For example, with the device of the fourth embodiment a formulation
can be applied in a
layer about the outside of the cylindrical housing.
As will be appreciated, the device of the present invention provides a
convenient way for
photodynamic therapy to be carried out in any orifice of the human or animal
body over long time
periods and at low fluence rates. This increases the convenience to the
patient and, in some cases,
the efficacy of the treatment.
CA 02748144 2011-06-22
WO 2010/078929 PCT/EP2009/009037
-24-
The embodiments described above are for illustration only and should not be
taken to limit
the scope of protection. The skilled man will appreciate that adjustments
could be made to these
embodiments without deviating from the scope of the claims. For example, the
housing may be
any shape which allows full and secure insertion into the orifice and the
exact shape of this
housing will depend on whether the device is intended for use on a human or
animal subject and
on the orifice where the treatment is to occur. In addition other forms of
control circuit and LED
array can be used within the invention.
